Table 1.
Demographic characteristics of the 51 diabetic patients.
Figure 1.
Decreased expression of NKG2D and NKp46 on NK cells from type 2 diabetes patients.
(A) Representative gating on CD3−/CD56+, CD56bright CD16dim/ne, CD56dim CD16bright and CD56− CD16+ cells. (B) NKG2D expression on NK cells from 25 healthy donors (HD) and 35 type 2 diabetic patients (T2D) as assessed by flow cytometry. One representative flow cytometry experiment is shown. (C) NKp46 expression quantified by FACS (n = 25); a representative analysis is shown. (**: P<0.01).
Table 2.
T cell and NK cell immunophenotypes in patients with type 2 diabetes and healthy donors.
Figure 2.
Correlation between plasma HbA1c levels and NKG2D expression on NK cells assesed by Spearman’s correlation.
A significant inverse correlation (n = 32, r = −0.5; P = 0.009) is revealed between the main marker of diabetic metabolic control and NKG2D expression on NK cells.
Figure 3.
Decreased functional properties of diabetic NK cells and effects of IL-15.
(A) CD107a degranulation assay using PBMCs from diabetic (n = 18) or control subjects (n = 16) challenged with K562 cells. Representative flow cytometry experiments are shown. (B) Overnight incubation in the presence of IL-15 (10 ng/mL) significantly increases NKG2D expression on NK cells from T2D patients (n = 7), as assessed by flow cytometry. A representative flow cytometry experiment is shown. (C) Stimulation with IL-15 (10 ng/mL) restores CD107a degranulation for PBMCs from diabetic patients (n = 7) challenged with K562 target cells. A representative flow cytometry experiment is shown *: P<0.05.
Figure 4.
Decreased NKp46 mRNA expression in NK cells from type 2 diabetic patients.
Quantitative RT-PCR was used to assess expression of NKp46 and NKG2D mRNAs in NK cells from healthy donors (n = 7) and diabetic patients (n = 7). Transcript levels are presented as mean±SEM. Only NKp46 mRNA is down-regulated. *:P<0.05.
Figure 5.
Tunicamycin induces ER stress and UPR activation, and decreases NKG2D expression in normal PBMCs in vitro.
PBMCs from healthy donors were incubated in the absence (Ctrl) or in the presence (Tm) of 1.25 µg/mL tunicamycin for 6 hours. (A) ER stress markers BiP, HERP, GRP94 and PDI, (B) IRE1α pathway marker spliced XBP1 (sXBP1) and (C) PERK pathway markers ATF4, GADD34 and CHOP mRNA amounts were determined by quantitative RT-PCR in normal PBMCs. Transcript levels are presented as mean±SEM (n = 6). *:P<0.05. (D) NKG2D, NKp46 and NKG2C expressions were quantified by flow cytometry (n = 12). *:P<0.05.
Figure 6.
Assessing ER stress and UPR activation in NK cells from diabetic patients.
mRNA levels for BiP, PDI and sXBP1 were quantified by quantitative RT-PCR in NK cells from healthy donors (n = 17) and type 2 diabetic patients (n = 18). Transcript levels are presented as mean±SEM. *:P<0.05; **: P<0.01.